Topic: Vertex Pharmaceuticals Inc.
NEW YORK (Reuters) - A closely watched experimental hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal late-stage trial of previously untreated patients, the company said on Tuesday. The results from the ...
Correction: Vertex Hepatitis C DrugIn a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, ...
Correction: Vertex Hepatis C DrugIn a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, ...
From Around the Web
Video Gallery
-
2009 Five Ventures Conference: Vertex Pharmaceutic...
TheFive Ventures Conference focuses on high-growth businesses in the following ...2010-03-31 -
Todd - Vertex Pharmaceuticals
On a recent visit to Vertex Pharmaceuticals, IAmBiotech spoke with ...2009-04-07 -
News Update: Morgan Stanley's Survey ...
Morgan Stanley analysts conducted an interview for Vertex Pharmaceuticals (NASDAQ ...2010-02-11
